China Resources Land (01109) accumulated contract sales of approximately 93.51 billion yuan in the first five months, an increase of 7.7% year-on-year.
China Resources Land Limited (01109) announced that, for the month ended May 31, 2026, the company and its subsidiaries (the Group) achieved a total contract sales amount of approximately RMB 23.51 billion and a total contract sales area of approximately 521,000 square meters. These figures represent a year-on-year increase of 28.1% and a decrease of 19.7%, respectively.
For the first five months of 2026, the total contract sales amount reached approximately RMB 93.51 billion and the total contract sales area amounted to approximately 2.364 million square meters, representing a year-on-year increase of 7.7% and a decrease of 26.6%, respectively.
CHINA RES LAND (01109) announced that for the month ending on May 31, 2026, the company and its subsidiaries (group) achieved a total contract sales amount of approximately RMB 23.51 billion, with a total contract sales building area of approximately 521,000 square meters, representing a year-on-year increase of 28.1% and a decrease of 19.7% respectively. The cumulative contract sales amount for the company up to May 2026 was approximately RMB 93.51 billion, with a total contract sales building area of approximately 2.364 million square meters, representing a year-on-year increase of 7.7% and a decrease of 26.6% respectively.
In May 2026, the group's recurring revenue was approximately RMB 4.4 billion, representing a year-on-year growth of 8.6%. Of this, the rental income from operating real estate leasing business was approximately RMB 3.0 billion, representing a year-on-year growth of 11.4%. The cumulative recurring revenue up to May 2026 was approximately RMB 22.01 billion, representing a year-on-year growth of 7.7%, with the rental income from operating real estate leasing business amounting to approximately RMB 15.0 billion, representing a year-on-year growth of 12.9%.
Related Articles

Buying low on Shenzhen Hepalink Pharmaceutical Group (09989) for two consecutive months, will the Hong Kong Stock Connect funds soon witness the reversal of the heparin cycle?

New Stock News | Leading supply chain company Andes Zhilian's Hong Kong IPO prospectus updated, achieving double high increase in revenue and net profit.

How strong is the demand for SpaceX (SPCX.US) IPO? Oversubscribed subscriptions, "greenshoe" exemption from commission, and options expected to open next week!
Buying low on Shenzhen Hepalink Pharmaceutical Group (09989) for two consecutive months, will the Hong Kong Stock Connect funds soon witness the reversal of the heparin cycle?

New Stock News | Leading supply chain company Andes Zhilian's Hong Kong IPO prospectus updated, achieving double high increase in revenue and net profit.

How strong is the demand for SpaceX (SPCX.US) IPO? Oversubscribed subscriptions, "greenshoe" exemption from commission, and options expected to open next week!

RECOMMEND





